0001104659-22-010399.txt : 20220201
0001104659-22-010399.hdr.sgml : 20220201
20220201170651
ACCESSION NUMBER: 0001104659-22-010399
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220131
FILED AS OF DATE: 20220201
DATE AS OF CHANGE: 20220201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Varian John
CENTRAL INDEX KEY: 0001416176
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33958
FILM NUMBER: 22579802
MAIL ADDRESS:
STREET 1: ARYX THERAPEUTICS,INC.
STREET 2: 6300 DUMBARTON CIRCLE
CITY: FREMONT
STATE: CA
ZIP: 94555
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc.
CENTRAL INDEX KEY: 0001390478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 6462005278
MAIL ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Galena Biopharma, Inc.
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: GALENA BIOPHARMA, INC.
DATE OF NAME CHANGE: 20110922
4
1
tm225088-5_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-31
0
0001390478
SELLAS Life Sciences Group, Inc.
SLS
0001416176
Varian John
C/O SELLAS LIFE SCIENCES GROUP, INC.,
7 TIMES SQUARE, SUITE 2503
NEW YORK
NY
10036
1
0
0
0
Common Stock
2022-01-31
4
A
0
1900
0.00
A
1900
D
Stock Option (Right to Buy)
5.34
2022-01-31
4
A
0
7125
0
A
2032-01-31
Common Stock
7125
7125
D
The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
/s/ John Varian
2022-02-01